| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
150,145 |
73,774 |
$6.98M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
144,182 |
71,391 |
$6.54M |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
66,630 |
42,766 |
$4.80M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
32,729 |
18,557 |
$2.14M |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
20,060 |
9,192 |
$1.75M |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
48,578 |
24,421 |
$666K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
19,628 |
3,389 |
$553K |
| 90832 |
Psychotherapy, 30 minutes with patient |
13,037 |
9,277 |
$521K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
6,207 |
3,314 |
$470K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,684 |
3,381 |
$343K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
3,702 |
3,134 |
$236K |
| 90791 |
Psychiatric diagnostic evaluation |
2,283 |
2,116 |
$221K |
| 82075 |
|
3,651 |
1,925 |
$113K |
| 90837 |
Psychotherapy, 53 minutes with patient |
1,088 |
882 |
$93K |
| 90834 |
Psychotherapy, 45 minutes with patient |
1,494 |
1,293 |
$87K |
| 80305 |
|
7,060 |
3,431 |
$70K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
918 |
854 |
$55K |
| H0038 |
Self-help/peer services, per 15 minutes |
659 |
240 |
$53K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,079 |
992 |
$45K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,075 |
954 |
$39K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,110 |
975 |
$33K |
| 99223 |
Prolong inpt eval add15 m |
456 |
408 |
$29K |
| 99205 |
Prolong outpt/office vis |
267 |
236 |
$24K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,804 |
1,594 |
$23K |
| 90962 |
|
541 |
454 |
$21K |
| 99406 |
|
801 |
702 |
$19K |
| 90961 |
|
238 |
221 |
$19K |
| 80306 |
|
920 |
485 |
$12K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
161 |
146 |
$12K |
| 81025 |
|
800 |
642 |
$11K |
| 90960 |
End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits |
125 |
115 |
$11K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
268 |
243 |
$11K |
| 97151 |
|
378 |
352 |
$5K |
| H0032 |
Mental health service plan development by non-physician |
125 |
121 |
$4K |
| 86328 |
|
32 |
29 |
$2K |
| 99236 |
Prolong inpt eval add15 m |
19 |
13 |
$2K |
| 99222 |
Initial hospital care, per day, moderate complexity |
35 |
27 |
$1K |
| 36415 |
Collection of venous blood by venipuncture |
278 |
255 |
$649.29 |
| 99239 |
Hospital discharge day management, more than 30 minutes |
13 |
13 |
$315.64 |
| 90935 |
Hemodialysis procedure with single evaluation by a physician |
44 |
24 |
$105.40 |